GH Research

GH Research is an Irish psychedelic pharmaceutical company developing novel therapies for psychiatric and neurological disorders and illnesses including treatment-resistant depression. The company predominantly focuses on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a naturally-occurring psychoactive substance from the tryptamine class, to develop its products.

Established in 2018, the Irish company has two products in its portfolio; 1) GH001, its lead drug candidate, which is administered via a proprietary inhalation approach, and 2) GH002, an injectable formulation of GH001. As of Q3 2023, GH001 was in Phase 2b clinical trial to evaluate the effectiveness for treatment-resistant depression and FDA had put its Investigational New Drug Application on clinical hold. It is also being investigated for bipolar II disorder and postpartum depression. The company also initiated a clinical pharmacology of its GH002 drug candidate in January 2023.

As of March 2023, GH Research has expanded its patent portfolio by adding 11 patent families related to the therapeutic use of mebufotenin for treating different disorders covering different aspects of mebufotenin, including administration through inhalation, buccal, sublingual, intravenous, or intramuscular, among others.

In June 2021, the company went public on the Nasdaq as the fourth psychedelic company to do so, raising USD 160 million. For FY2022 , the company’s net losses significantly increased by 145% YoY to USD 22.5 million.